Effects of adding luteinizing hormone activity to gonadotropin releasing hormone antagonist protocols may differ according to age
- 12 March 2010
- journal article
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 26 (4) , 256-260
Abstract
Objective. In spite of previous reports on the beneficial effects of adding exogenous luteinizing hormone (LH) activity to gonadotropin releasing hormone (GnRH) antagonist protocols for conventional in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), these effects in various age groups are still controversial. This study was performed to evaluate the clinical efficacy of adding LH activity to GnRH antagonist protocols according to patient's age. Methods. In this medical record review, responses to controlled ovarian hyperstimulation (COH) and IVF/ICSI outcomes were compared between follicle stimulating hormone (FSH) alone and FSH supplemented with LH activity groups in women ≤35 years (n = 135) and those >35 years (n = 97), respectively. Results. Estradiol level on hCG day in LH-added group was higher (2.150.6 ± 1.345.1 pg/ml vs. 1.606.2 ± 994.6 pg/ml, P = 0.011) in women ≤35 years, while it did not differ in those >35 years. Less oocytes were retrieved in LH-added group of women >35 years (8.1 ± 6.5 vs. 5.7 ± 3.0, P = 0.013), however, this figure did not differ in those ≤35 years. Regardless of age, the clinical pregnancy rates were not different between the two groups. Conclusions. Supplementation of exogenous LH activity to GnRH antagonist protocols affects the COH outcomes. These LH-adding effects may vary according to patient's age.Keywords
This publication has 20 references indexed in Scilit:
- Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cyclesFertility and Sterility, 2008
- Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysisHuman Reproduction Update, 2007
- Comparison of the efficacy and safety of a new recombinant human follicle‐stimulating hormone (DA‐3801) with follitropin‐α (Gonal‐F®) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technologyJournal of Obstetrics and Gynaecology Research, 2007
- Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization proceduresFertility and Sterility, 2007
- Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: Comparison of r-FSH alone and in combination with r-LHEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2006
- Are endogenous LH levels during ovarian stimulation for IVF using GnRH analogues associated with the probability of ongoing pregnancy? A systematic reviewHuman Reproduction Update, 2005
- Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonistsFertility and Sterility, 2005
- A preliminary study on reduced dose (33 or 25 μg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoingin vitrofertilization–embryo transferGynecological Endocrinology, 2005
- Luteinizing hormone supplementation increases pregnancy rates in gonadotropin-releasing hormone antagonist donor cyclesFertility and Sterility, 2004
- A pilot study of the use of low dose human menopausal gonadotropin in ovulation inductionEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2003